The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This project was funded by a grant from the American Cancer Society (RSG-11-098-01-CPHPS to Dr. Neuner).
YenTWCzypinskiLKSparapaniRA. Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer2011;117:398–405.
AmirESerugaBNiraulaS. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst2011;103:1299–1309.
NeunerJMYenTWSparapaniRA. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int2011;22:2847–2855.
LonningPEGeislerJKragLE. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol2005;23:5126–5137.
HillnerBEIngleJNChlebowskiRT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003;21:4042–4057.
LimLSHoeksemaLJSherinK. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med2009;36:366–375.
NelsonHDHaneyEMDanaT. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med2010;153:99–111.
EarleCCBursteinHJWinerEP. Quality of non–breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol2003;21:1447–1451.
SnyderCFFrickKDKantsiperME. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol2009;27:1054–1061.
LigibelJO'MalleyAJFisherM. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat2012;134:1305–1313.
SpanglerLYuOLoggersE. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Women's Health2013;22:132–140.
Early Breast Cancer Trialists' Collaborative Group: aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet2015;386:1341–1352.
NattingerABLaudPWBajorunaiteR. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res2004;39(6 Pt 1):1733–1749.
KlabundeCNLeglerJMWarrenJL. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol2007;17:584–590.
HowellACuzickJBaumM. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet2005;365:60–62.
van de VeldeCJReaDSeynaeveC. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet2011;377:321–331.
Dhesy-ThindSK. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?J Clin Oncol2012;30:1408–1410.
JacobsenSJGoldbergJMilesTP. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health1990;80:871–873.
BanksEReevesGKBeralV. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLOS Med2009;6:e1000181.
NeunerJMBinkleyNSparapaniRA. Bone density testing in older women and its association with patient age. J Am Geriatr Soc2006;54:485–489.
CurtisJRCarboneLChengH. Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res2008;23:1061–1067.
AftRNaughtonMTrinkausK. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol2010;11:421–428.
GnantMMlineritschBStoegerH. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol2011;12:631–641.
EidtmannHde BoerRBundredN. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol2010;21:2188–2194.
PerssonIAdamiHOMcLaughlinJK. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control1994;5:523–528.
ChenZMaricicMAragakiA. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int2009;20:527–536.
ItoKBlinderVSElkinEB. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol2012;30:1468–1475.